DRUG DELIVERY DEVICE AND METHOD FOR ASSEMBLING A DRUG DELIVERY DEVICE

A drug delivery device (1) comprises a first component (6) and a second component (9), wherein a substance (16) e.g. grease, is provided on at least one of the first component (6) and the second component (9). An inner friction or viscosity of the substance (16) is great enough to stabilize at least one of the orientation and the position of the first component (6) and the second component (9) with respect to another. The inner friction or viscosity of the substance (16) is small enough to allow relative movement of the first component (6) and the second component (9) necessary for the intended operation of the device (1). Furthermore, a method for assembling a drug delivery device (1) is provided.

(57) Abstract: A drug delivery device (1) comprises a first component (6) and a second component (9), wherein a substance (16) e.g. grease, is provided on at least one of the first component (6) and the second component (9). An inner friction or viscosity of the substance (16) is great enough to stabilize at least one of the orientation and the position of the first component (6) and the second component (9) with respect to another. The inner friction or viscosity of the substance (16) is small enough to allow relative movement of the first component (6) and the second component (9) necessary for the intended operation of the device (1). Furthermore, a method for assembling a drug delivery device (1) is provided.

(54) Title: DRUG DELIVERY DEVICE AND METHOD FOR ASSEMBLING A DRUG DELIVERY DEVICE

(3) Prior Art Disclosure

[51] International Patent Classification:
A61M 5/318 (2006.01)

(21) International Application Number:
PCT/EP2011/068603

(22) International Filing Date:
25 October 2011 (25.10.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10188657.0 25 October 2010 (25.10.2010) EP

(71) Applicant (for all designated States except US):
SANOFI-AVENTIS DEUTSCHLAND GMBH [DE/DE]; Sanofi-Aventis Deutschland GmbH, Brinlingstrasse 50, 65929 Frankfurt (DE).

(72) Inventors; and


(81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIP (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, [Continued on next page]
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD),
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT,
LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS,
SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— of inventorship (Rule 4.17(iv))

Published:
— with international search report (Art. 21(3))
Description

DRUG DELIVERY DEVICE AND METHOD FOR ASSEMBLING A DRUG DELIVERY DEVICE

This disclosure relates to a drug delivery device and to a method for assembling a drug delivery device.

In a drug delivery device a bung is, often, provided within a cartridge that contains a drug. The bung is displaced with respect to the cartridge by a piston rod for delivering a dose of the drug. The piston rod may be driven by a drive mechanism of the drug delivery device.

A drug delivery device is described in document EP 1 923 093, for example.

It is an object of the present disclosure to facilitate provision of an improved drug delivery device, for example a device with high dose accuracy or with increased user safety.

This object may be achieved by the subject-matter of the independent claims. Further features are the subject-matter of the dependent claims.

According to one aspect, a drug delivery device is provided. The drug delivery device comprises a first component. The drug delivery device comprises a second component. A substance is provided on at least one of the first component and the second component. The substance comprises an inner friction. The inner friction is preferably great enough to stabilize the orientation and/or the position of the first component and the second component with respect to one another. The position may comprise at least one of an axial and an angular position of the first component and the second component with respect to one another. The inner friction of the substance is small enough to allow relative axial and/or rotational movement of the first component and the
second component necessary for intended operation of the device, e.g. for at least one of setting and dispensing of a dose of a drug.

Relative movement of the first component and the second component may comprise at least one of axial and/or rotational movement of the first component with respect to the second component and axial and/or rotational movement of the second component with respect to the first component.

The substance may pose a threshold of impact counteracting any force acting on the respective component. The threshold has to be overcome in order to initiate relative movement of the first and the second component with respect to one another. The threshold, in particular the inner friction of the substance, may be chosen such that any force arising beyond the intended operation of the device and acting on the respective component, e.g. a force arising from movement possible due to play between the components, is prevented from overcoming the threshold. Thus, unintentional relative movement of the first component and the second component may be prevented. Accordingly, a predetermined position of the first component and the second component with respect to one another may be maintained by means of the substance. Dose accuracy may be increased in this way.

The threshold, in particular the inner friction of the substance, may be chosen such that any force arising from intended operation of the device and acting on the respective component, e.g. a force caused by a drive mechanism of the device, is allowed to overcome the threshold. Thus, intentional relative movement of the first component and the second component for operation of the device may be allowed.

According to an embodiment, the inner friction of the substance is great enough to prevent relative axial and/or rotational movement of the first and second component caused by an outer impact or by a vibration of the device.

The device may, for example, be subject to vibrations, e.g. during transport of the device. Forces arising from said vibrations acting on the first and the second component
may be counteracted by means of the substance, in particular due to the inner friction of
the substance.

According to an embodiment, the inner friction of the substance is great enough to
prevent relative axial and/or rotational movement of the first and the second component
arising from a manufacturing tolerance of at least one of the first component and the
second component. Additionally or alternatively, the inner friction of the substance may
be great enough to prevent relative movement of the first and the second component
arising from manufacturing tolerances during assembly of the device.

Said manufacturing tolerances may lead to play between the first component and the
second component. The first component and the second component may be prone to
relative movement with respect to one another due to said play. However, this may
reduce dose accuracy of the device. The inner friction of the substance is preferably
great enough to prevent relative movement due to said play.

According to an embodiment, a force applied to at least one of the first and the second
component during intended operation of the device is great enough to overcome the
inner friction of the substance.

Intended operation of the device may comprise the operation of setting and/or delivering
of a dose of a drug from the device, for example. The force applied on at least one of
the first and the second component during said operations may be great enough and,
accordingly, the inner friction of the substance may be small enough to overcome the
inner friction, the first component and the second component thus being moveable with
respect to one another. Intended use of the device may be guaranteed in this way.

According to an embodiment, the first component and the second component are part of
a drive mechanism of the device. Relative movement of the first component and the
second component may be allowed as far as being necessary for operation of the drive
mechanism, e.g. for setting and/or delivering of a dose of the drug.
According to an embodiment, an outer shape of the first component and the second component is predetermined by the intended operation of the device, in particular the intended operation of the drive mechanism.

In particular, modification of the first component and the second component, e.g. of their outer shape, may not be necessary to prevent unintentional relative movement of the first component and the second component. In this way, a cost-effective drug delivery device may be achieved.

According to an embodiment, the substance is adhesively coupled to an outer surface, e.g. a bearing surface, of at least one of the first component and the second component.

The respective bearing surface may be adapted and arranged to mechanically cooperate with the bearing surface of the other one of the first component and the second component. Upon mechanical cooperation of the bearing surfaces, relative movement of said components may be prevented by means of the substance applied to, in particular coupled to, the respective bearing surface counteracting a force which tends to initiate relative movement of the first and the second component. The material property of the substance may be chosen such that the substance is coupled to the outer surface of at least one of the first component and the second component in such a way that it is not removed or destroyed upon mechanical cooperation of the first component and the second component, in particular of their bearing surfaces.

According to an embodiment, the substance comprises a viscous fluid. The substance may comprise a grease, for example.

According to an embodiment, the first component comprises a dose button of the device. The dose button may be configured to be actuated by a user for at least one of setting and dispensing a dose of the drug from the device.
According to an embodiment, the second component comprises a dose indicator element of the device. The dose indicator element may be configured for indicating a number of the drug dispensed from the device.

According to an embodiment, the dose button comprises a tubular shape. The dose indicator element may comprise a ring-like shape. The dose indicator element may be permanently or releasably arranged within the tube of the dose button.

During insertion of the dose indication element into the dose button, a force may arise which tends to alter the relative position of the dose button and the dose indication element. The substance which may, for example, be applied to the bearing surface of the dose indication element, may counteract said force, hence, preventing unintentional movement of the dose indication element with respect to the dose button during insertion.

A further aspect relates to a method for assembling a drug delivery device. The drug delivery device comprises a first component. The drug delivery device comprises a second component. In a first step, a substance is applied to at least one of the first component and the second component. The substance may adhesively couple to the respective component, e.g. to a bearing surface of the respective component. In a further step, the second component and the first component are permanently or releasably mounted together. An inner friction of the substance is great enough to releasably, in particular temporarily, fix an axial and/or angular position of the second component and the first component with respect to one another during the mounting. In a third step, a third component of the device is permanently or releasably mounted to the second component. Said mounting may cause an axial and/or rotational force acting on the second component. Relative movement of the first component and the second component during mounting of the third component, in particular arising from said force, may be prevented by means of the substance.

During assembly of the device, the axial and/or rotational position of the second component with respect to the first component may be maintained by means of the
substance. The inner friction of the substance had to be overcome by the forces acting onto the first and/or the second component during assembly for initiating relative movement. However, the inner friction may be great enough to compensate said forces, thus preventing unintentional relative movement of the first component and the second component during assembly. This may help to maintain a predetermined position of the first component with respect to the second component with respect to one another, thus increasing dose accuracy of the device.

Of course, features described above in connection with different aspects and embodiments may be combined with each other and with features described below.

Further features, advantages and refinements become apparent from the following description of the exemplary embodiments in connection with the accompanying figures.

Figure 1 schematically shows a perspective side view of an exemplary embodiment of a drug delivery device,

Figure 2 schematically shows an embodiment of a dose indication element prior to insertion of the dose indication element,

Figure 3 schematically shows introduction of the dose indicator element of Figure 2 into a dose button during assembly of the device shown in Figure 1,

Figure 4 schematically shows the dose indicator element shown in Figure 2 arranged within the dose button.

Like elements, elements of the same kind and substantially equivalent or identically acting elements may be provided with the same reference numerals in the figures.

In Figure 1 a drug delivery device 1 is shown. The drug delivery device 1 comprises a housing 2. The drug delivery device 1 and the housing 2 have a distal end 7 and a proximal end 8. The term "distal end" designates that end of the drug delivery device 1
or a component thereof which is or is to be arranged closest to a dispensing end of the
drug delivery device 1. The term "proximal end" designates that end of the device 1 or a
component thereof which is or is to be arranged furthest away from the dispensing end
of the device 1.

The housing 2 may be designed to enable a safe and comfortable handling of the drug
delivery device 1. The housing 2 may be configured to house, fix, protect or guide inner
components of the drug delivery device 1, e.g. members of a drive mechanism which is
explained later on in more detail. Preferably, the housing 2 limits or prevents the
exposure of the inner components to contaminants such as liquid, dirt or dust. The
housing 2 may be a unitary or a multipart component. The housing 2 may have a
tubular shape, as shown in Figure 1. Alternatively, the housing 2 may have a non-
tubular shape.

The device 1 comprises a cartridge holder 3. The device 1 comprises a cartridge 4. The
cartridge 4 is, preferably releasably, secured to the cartridge holder 3. The cartridge
holder 3 stabilizes the cartridge 4 mechanically. The cartridge holder 3 and the housing
2 may be, preferably releasably, secured to one another. For this purpose, a proximal
end of the cartridge holder 3 may be secured to a distal end of the housing 2, e.g. by
means of a bayonet fitting. A cartridge holder 3 which is releasably secured to the
housing 2 may be detached from the housing 2, for example in order to allow for
introducing a replacement cartridge into the device 1.

The cartridge 4 may hold a plurality of doses of a drug 13. The term "drug" as used
herein, preferably means a pharmaceutical formulation containing at least one
pharmacologically active compound, wherein in one embodiment the pharmacologically
active compound has a molecular weight up to 1500 Da and/or is a peptide, a
proteine, a polysaccharide, a vaccine, a DNA, a RNA, an enzyme, an antibody, a
hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically
active compound, wherein in a further embodiment the pharmaceutically active
compound is useful for the treatment and/or prophylaxis of diabetes mellitus or
complications associated with diabetes mellitus such as diabetic retinopathy,
thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis.

In a further embodiment the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy.

In a further embodiment the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exedin-3 or exedin-4 or an analogue or derivative of exedin-3 or exedin-4.

Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.

Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.

Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
Exendin-4 derivatives are for example selected from the following list of compounds:

\[
\begin{align*}
\text{H-(Lys)4-des Pro36, des Pro37 Exendin-4(1-39)-NH2,} \\
\text{H-(Lys)5-des Pro36, des Pro37 Exendin-4(1-39)-NH2,} \\
\text{des Pro36 [Asp28] Exendin-4(1-39),} \\
\text{des Pro36 [IsoAsp28] Exendin-4(1-39),} \\
\text{des Pro36 [Met(0)14, Asp28] Exendin-4(1-39),} \\
\text{des Pro36 [Met(0)14, IsoAsp28] Exendin-4(1-39),} \\
\text{des Pro36 [Trp(02)25, Asp28] Exendin-4(1-39),} \\
\text{des Pro36 [Trp(02)25, IsoAsp28] Exendin-4(1-39),} \\
\text{des Pro36 [Met(0)14 Trp(02)25, Asp28] Exendin-4(1-39),} \\
\text{des Pro36 [Met(0)14 Trp(02)25, IsoAsp28] Exendin-4(1-39); or} \\
\text{des Pro36 [Asp28] Exendin-4(1-39),} \\
\text{des Pro36 [IsoAsp28] Exendin-4(1-39),} \\
\text{des Pro36 [Met(0)14, Asp28] Exendin-4(1-39),} \\
\text{des Pro36 [Met(0)14, IsoAsp28] Exendin-4(1-39),} \\
\text{des Pro36 [Trp(02)25, Asp28] Exendin-4(1-39),} \\
\text{des Pro36 [Trp(02)25, IsoAsp28] Exendin-4(1-39),} \\
\text{des Pro36 [Met(0)14 Trp(02)25, Asp28] Exendin-4(1-39),} \\
\text{des Pro36 [Met(0)14 Trp(02)25, IsoAsp28] Exendin-4(1-39),} \\
\text{wherein the group \text{-Lys6-NH2} may be bound to the C-terminus of the Exendin-4 derivative;}
\end{align*}
\]

or an Exendin-4 derivative of the sequence

\[
\begin{align*}
\text{H-(Lys)6-des Pro36 [Asp28] Exendin-4(1-39)-Lys6-NH2,} \\
\text{des Asp28 Pro36, Pro37, Pro38 Exendin-4(1-39)-NH2,} \\
\text{H-(Lys)6-des Pro36, Pro38 [Asp28] Exendin-4(1-39)-NH2,} \\
\text{H-Asn-(Glu)5des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-NH2,} \\
\text{H-(Lys)6-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,} \\
\text{H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,} \\
\text{H-(Lys)6-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,} \\
\text{H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,}
\end{align*}
\]
H-(Lys)6-des Pro36 [Trp(02)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
H-des Asp28 Pro36, Pro37, Pro38 [Trp(02)25] Exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(02)25, Asp28] Exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(02)25, Asp28] Exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Trp(02)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(02)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(02)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36 [Met(0)14, Asp28] Exendin-4(1-39)-Lys6-NH2,
des Met(0)14 Asp28 Pro36, Pro37, Pro38 Exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-Lys6-des Pro36 [Met(0)14, Trp(02)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
H-des Asp28 Pro36, Pro37, Pro38 [Met(0)14, Trp(02)25] Exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(0)14, Trp(02)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
des Pro36, Pro37, Pro38 [Met(0)14, Trp(02)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(0)14, Trp(02)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2;

or a pharmaceutically acceptable salt or solvate of any one of the afore-mentioned Exedrin-4 derivative.

Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin,
Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.

A polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.

Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. HCl or HBr salts. Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group. Further examples of pharmaceutically acceptable salts are described in "Remington's Pharmaceutical Sciences" 17. ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 and in Encyclopedia of Pharmaceutical Technology.

Pharmaceutically acceptable solvates are for example hydrates.

The drug delivery device 1 may comprise a needle assembly (not explicitly shown), comprising a needle. The needle assembly may be releasably attached to the cartridge holder 3. Alternatively, the drug delivery device 1 may be a needle-free device.

The cartridge 4 comprises an outlet 11. The outlet 11 may be covered by a membrane 10. The membrane 10 may protect the drug 13 against external influences during storage of the cartridge 4. The cartridge 4 comprises a bung 5. The bung 5 is moveably retained in the cartridge 4. The bung 5 seals the cartridge 4 proximally. Movement of the bung 5 in the distal direction with respect to the cartridge 4 causes the drug 13 to be
dispensed from the cartridge 4 through the outlet 11, provided that fluid communication was established between the interior and the exterior of the cartridge 4, e.g. when the membrane 10 is pierced by the needle.

The drug delivery device 1 may be an injection device. The drug delivery device 1 may be a pen-type device, in particular a pen-type injector. The device 1 may be a disposable or a re-usable device. The device 1 may be configured to dispense variable doses, in particular user-settable doses, of the drug 13. Alternatively, the device 1 may be configured to dispense fixed doses of the drug 13, in particular pre-set doses which may not be varied by the user. The drug delivery device 1 may be a manually, in particular a non-electrically, driven device.

The drug delivery device 1 comprises a piston rod 12. The piston rod 12 may be made of a flexible or a rigid material. The piston rod 12 may have a circular or a non-circular cross-section. The piston rod 12 may be a simple rod, a lead-screw, a rack, a pinion system or the like. The piston rod 12 may be of unitary or multipart construction.

The piston rod 12 operates through the housing 2 of the drug delivery device 1. The piston rod 12 is designed to transfer force to the bung 5, thereby driving the bung 5 in the distal direction with respect to the cartridge 4 and the housing 2. In this way, a dose of the drug 13 is dispensed from the cartridge 4 provided that the outlet 11 was opened, e.g. the membrane 10 was pierced by the needle as described above. The size of the dispensed dose is determined by the distance by which the bung 5 is displaced in the distal direction with respect to the housing 2.

A bearing member 14 is arranged between the bung 5 and the piston rod 12 to advance the bung 5. The bearing member 14 is displaceable together with the piston rod 12 with respect to the housing 2. The piston rod 12 is preferably rotatable with respect to the bearing member 14. In this way, the risk that the rotating piston rod 12 drills into the bung 5 and thereby damages the bung 5 is reduced.
The device 1 comprises a drive mechanism. The drive mechanism is configured to drive the piston rod 12. In particular, the drive mechanism is configured for transferring force, preferably user-exerted force, particularly preferably manually exerted force, to the bung 5 by means of the piston rod 12 for displacing the bung 5 with respect to the cartridge 4 in the distal direction. A dose of the drug 13 may be dispensed from the cartridge 4 in this way.

The drive mechanism comprises a dose button 6. The dose button 6 may comprise a tubular shape. The dose button 6 may comprise or may be embodied as a sleeve. The dose button 6 is configured to be gripped by the user. The dose button 6 is moveable with respect to the housing 2. The dose button 6 may be moveable in the proximal direction with respect to the housing 2 for setting a dose of the drug 13. The dose button 6 may be moveable in the distal direction with respect to the housing 2 for delivering the set dose. The distance by which the dose button 6 is displaced with respect to the housing 2 during setting of the dose may determine a size of the dose. The dose button 6 comprises a window 15.

The drive mechanism comprises a dose indication element 9. The dose indication element 9 may comprise a ring-like shape. The dose indication element 9 comprises a size suited for introduction of the dose indication element 9 into the dose button 6 during an assembly of the device 1. Once introduced into the dose button 6, the dose indication element 9 is, at least partly, visible through the window 15. The dose indication element 9 may be at least one of rotatable and axially moveable with respect to the dose button 6 during operation of the device 1, e.g. during setting and/or delivering of a dose of the drug 13.

The dose indication element 9 comprises an outer surface, in particular a bearing surface 17 (see Figure 2). The bearing surface 17 is configured to mechanically cooperate with, in particular to contact, an inner surface, e.g. a bearing surface 18 (see Figure 4), of the dose button 6 which is explained later on in more detail.
The dose indication element 9 may be configured to display the number of doses of the drug 13 dispensed from the device, for example. Alternatively, the dose indication element 9 may be adapted to indicate at least two different operation conditions of the device 1, e.g. an unprimed condition and a primed condition, of the device 1. When the device 1 is in the primed condition, a priming dose of the drug 13 was dispensed from the device 1.

Unintentional movement, e.g. rotation, of the dose indication element 9 with respect to the dose button 6 may lead to displaying a wrong number of doses dispensed from the device 1 or to displaying a wrong operation condition of the device 1. In the latter case, for example, an unintentionally rotated dose indication element 9 may indicate a primed condition of the device 1, although no priming dose has been dispensed so far. This may have fatal or even lethal consequences for the user. Accordingly, it is crucial to prevent unintentional movement of the dose indication element 9 with respect to the dose button 6, in particular to accurately maintain the rotational position of the dose indication element 9 with respect to the dose button 6.

In this context, unintentional movement may comprise each kind of movement, e.g. rotational and/or axial movement, which is not necessary for the intended operation of the device 1, e.g. for priming the device 1, for setting a dose and/or delivering the set dose from the device 1. For example, unintentional movement may occur while inserting the dose indication element 9 into the dose button 6 during assembly of the device 1. Additionally or alternatively, unintentional movement may arise from manipulation of the device 1 during assembly, e.g. introduction of a further component, e.g. the piston rod 12, into the device 1. Additionally or alternatively, unintentional movement may be possible due to tolerances between the dose indication element 9 and the dose button 6 arising from the assembly of the device 1. Additionally or alternatively, unintentional movement may be possible, during intended operation of the device 1, due to manufacturing tolerances of at least one of the dose indication element 9 and the dose button 6 which may lead to play between the dose indication element 9 and the dose button 6. Additionally or alternatively, unintentional movement may arise from an outer impact and/or by a vibration of the device 1 during intended operation of the device 1.
In order to prevent unintentional movement of the dose indication element 9 with respect to the dose button 6, a substance 16 (see Figure 2) may be applied to at least one of the dose indication element 9 and the dose button 6, which is explained in connection with Figures 2 to 4.

Figure 2 shows an embodiment of the dose indication element 9 prior to insertion of the dose indication element 9 into the dose button 6.

As shown in Figure 2, the substance 16 is applied to the bearing surface 17 of the dose indication element 9. Additionally or alternatively, the substance 16 may be applied to the bearing surface 18 of the dose button 6 (not explicitly shown). The substance 16 is adhesively coupled to the bearing surface 17 of the dose indication element 9 and/or the bearing surface 18 of the dose button 6. In particular, mechanical cooperation of the respective bearing surface 17, 18 providing the substance 16 and the other one of the bearing surfaces 17, 18 may not lead to removal of the substance 16.

The substance 16 is applied prior to assembly of the device 1 and, in particular, prior to insertion of the dose indication element 9 into the dose button 6 (see Figures 3 and 4). Once the dose indication element 9 is inserted into the dose button 6, the bearing surfaces 17, 18 mechanically cooperate, thus bringing the substance 16 into contact with the bearing surface 18 of the dose button 6 (see Figure 3).

The substance 16 has an inner friction. The inner friction has to be overcome, e.g. by a force exerted by the drive mechanism onto the dose indication element 9 and/or the dose button 6, for achieving relative movement of the dose button 6 and the dose indication element 9. In particular, the inner friction may be such that unintentional relative movement of the dose button 6 and the dose indication element 9, e.g. during assembly, is prevented with relative movement necessary for operation of the device 1 being allowed, which is explained in more detail in connection with Figures 3 and 4. The inner friction may comprise a constant value in the range of operating temperatures of
the device 1, e.g. in the range of 0° and 40°. The substance 16 may comprise a viscous fluid, e.g. a grease.

Figure 3 shows the insertion of the dose indication element 9 into the dose button 6 during assembly of the device 1.

After the substance 16 was applied, the dose indication element 9 is inserted into the dose button 6, as shown in Figure 3. Upon insertion, the bearing surfaces 17, 18 mechanically cooperate with one another. Accordingly, the substance 16 is brought into contact with the respective bearing surface 17, 18. Due to said cooperation, the dose button 6 and the dose indication element 9 are temporarily secured to one another. In particular, the dose button 6 and the dose indication element 9 are secured against unintentional relative movement, e.g. rotation, by means of the substance 16, in particular due to the inner friction of the substance 16. In other words, the applied amount of the substance 16 and/or its inner friction is great enough to stabilize the orientation, in particular the angular position, of the dose indication element 9 with respect to the dose button 6 during insertion of the dose indication element 9 into the dose button 6. The applied amount of the substance 16 and/or its inner friction is great enough to compensate the forces acting on the dose indication element 9 during insertion of the dose indication element 9. In this way, it is guaranteed that the dose indication element 9 is positioned at its predetermined angular position within the dose button 6 after assembly was completed, e.g. the dose indication element 9 may indicate after assembly that zero doses have been dispensed from the device 1 so far.

Figure 4 shows a part of the device 1 shown in Figure 1. In particular, Figure 4 shows a cross-sectional view of the dose button 6 after insertion of the dose indication element 9 into the dose button 6.

After insertion of the dose indication element 9, further components of the device 1 may be assembled, e.g. the piston rod 12 may be introduced into the device 1 (not explicitly shown in Figure 4). Thereby, the substance 16 applied to the respective bearing surface 17, 18 again prevents rotation of the dose indication element 9 by counteracting the
forces acting on the dose indication element 9 when further components are introduced into the device 1. In particular, the applied amount of the substance 16 and/or its inner friction is also great enough to stabilize the orientation, in particular the angular position, of the dose indication element 9 with respect to the dose button 6 during insertion of the further components, e.g. the piston rod 12.

After assembly was completed, the device 1 may be ready for operation. The bearing surfaces 17, 18 are still in mechanical cooperation with one another. Accordingly, the substance 16 is in contact with the respective bearing surface 17, 18. The applied amount of the substance 16 and/or its inner friction is great enough to stabilize the intended angular and/or axial position of the dose indication element 9 with respect to the dose button 6 during the intended operation of the device 1, in particular during operation of the drive mechanism. In this way, unintentional movement of the dose indication element 9 with respect to the dose button 6, e.g. movement arising from forces acting on the dose indication element 9 due to an outer impact as described above, is prevented during operation. However, the applied amount of the substance 16 and/or its inner friction is small enough to allow movement of the dose indication element 9 with respect to the dose button 6 which is necessary during the intended operation of the device 1, e.g. for rotation of the dose indication element 9 for indicating the dispensed number of doses of the drug 13. In particular, a force applied to the dose indication element 9 by means of the drive mechanism during operation of the device 1 is great enough to overcome the inner friction of the substance 16. The inner friction of the substance 16 is small enough such that relative movement of the dose indication element 9 with respect to the dose button 6 during intended operation is enabled without destroying the respective bearing surface 17, 18 or the respective component of the device 1, i.e. the dose indication element 9 or the dose button 6.

As described above, the substance 16 may be applied to the dose indication element 9. However, the substance 16 may be applied to any other component of the device 1, in particular components of the drive mechanism, to be secured against unintentional movement during assembly and intended operation of the device 1. Said components may comprise the piston rod 12, for example.
The outer shape of said components, e.g. of the dose indication element 9, the dose button 6, the piston rod 12, may be determined by the intended operation of the drive mechanism. In particular, the outer shape may not be suited to restrict or even prevent unintentional movement as described above by means of further elements of the device 1, e.g. holding features, mechanically interacting with the respective component.

Other implementations are within the scope of the following claims. Elements of different implementations may be combined to form implementations not specifically described herein.
Reference numerals

1 Drug delivery device
2 Housing
5 3 Cartridge holder
4 Cartridge
5 Bung
6 Dose button
7 Distal end
10 8 Proximal end
9 Dose indication element
10 Membrane
11 Outlet
12 Piston rod
15 13 Drug
14 Bearing member
15 Window
16 Substance
17 Bearing surface
20 18 Bearing surface
Claims

1. A drug delivery device (1) comprising a first component (6) and a second component (9), wherein a substance (16) is provided on at least one of the first component (6) and the second component (9), wherein an inner friction of the substance (16) is great enough to stabilize at least one of the orientation and the position of the first component (6) and the second component (9) with respect to one another, and wherein the inner friction of the substance (16) is small enough to allow relative movement of the first component (6) and the second component (9) necessary for the intended operation of the device (1).

2. The drug delivery device (1) according to claim 1, wherein the inner friction of the substance (16) is great enough to prevent relative movement of the first and second component (9) caused by an outer impact or by a vibration of the device (1).

3. The drug delivery device (1) according to claim 1 or claim 2, wherein the inner friction of the substance (16) is great enough to prevent relative movement of the first and the second component (9) arising from a manufacturing tolerance of at least one of the first component (6) and the second component (9) and/or during assembly of the device (1).

4. The drug delivery device (1) according to any of the previous claims, wherein a force applied to at least one of the first component (6) and the second component (9) during intended operation of the device (1) is great enough to overcome the inner friction of the substance (16).

5. The drug delivery device (1) according to any of the previous claims, wherein relative movement between the first component (6) and the second component (9) comprises at least one of relative rotational and axial movement.

6. The drug delivery device (1) according to any of the previous claims,
wherein the first component (6) and the second component (9) are part of a drive mechanism of the device (1), and wherein relative movement of the first and second component (6, 9) is allowed so far as being necessary for operation of the drive mechanism.

7. The drug delivery device (1) according to any of the previous claims, wherein an outer shape of the first component (6) and the second component (9) is predetermined by the intended operation of the device (1).

8. The drug delivery device (1) according to any of the previous claims, wherein the substance (16) is adhesively coupled to a bearing surface (17, 18) of at least one of the first component (6) and the second component (9).

9. The drug delivery device (1) according to any of the previous claims, wherein the substance (16) comprises a viscous fluid.

10. The drug delivery device (1) according to any of the previous claims, wherein the first component (6) comprises a dose button (6) of the device (1) which is configured to be actuated by a user for at least one of setting and dispensing a dose of a drug (13) from the device (1).

11. The drug delivery device (1) according to any of the previous claims, wherein the second component (9) comprises a dose indication element (9) of the device (1) which is configured for indicating a number of doses of a drug (13) dispensed from the device (1).

12. The drug delivery device (1) according to claim 10 and claim 11, wherein the dose button (6) comprises a tubular shape, the dose indication element (9) comprises a ring-like shape, and wherein the dose indication element (9) is arranged within the dose button (6).
13. A method for assembling a drug delivery device (1) comprising a first component (6) and a second component (9), the method comprising the steps of:
- applying a substance (16) to at least one of the first component (6) and the second component (9),
- mounting the second component (9) and the first component (6) together, an inner friction of the substance (16) being great enough to releasably fix a position of the second component (9) and the first component (6) with respect to one another during the mounting,
- mounting a third component of the device (1) to the second component (9), relative movement of the first component (6) and the second component (9) during mounting of the third component being prevented by means of the substance (16).

14. The method of claim 13, wherein the inner friction of the substance (16) is great enough to prevent relative movement of the second component (9) and the first component (6) with respect to one another caused by manipulation of the device (1) during the assembly.
INTERNATIONAL SEARCH REPORT

PCT/EP2011/068603

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61M5/315
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal , WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 2008/015066 AI (NOVO NORDISK AS [DK]; SIVEBAEK ION MARIUS [DK]) 7 February 2008 (2008-02-07) page 1, line 7 - page 2, line 8</td>
<td>1-14</td>
</tr>
<tr>
<td>X</td>
<td>WO 2009/030975 AI (BECTON DICKINSON FRANCE [FR]; BOULANGE LAURENCE [FR]; CROZET FREDERIQU) 12 March 2009 (2009-03-12) page 1, line 1 - page 2, line 30</td>
<td>1-14</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:
  "A" document defining the general state of the art which is not considered to be of particular relevance
  "E" earlier document but published on or after the international filing date
  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  "O" document referring to an oral disclosure, use, exhibition or other means
  "P" document published prior to the international filing date but later than the priority date claimed
  "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  "A" document member of the same patent family

Date of the actual completion of the international search: 5 December 2011

Date of mailing of the international search report: 12/12/2011

Name and mailing address of the ISA:
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer
Krassow, Heiko
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>US 2003187405 AI</td>
<td>02-10-2003</td>
<td>AT 285262 T</td>
<td>15-01-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 7229301 A</td>
<td>08-04-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2001272293 B2</td>
<td>02-02-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 0114151 A</td>
<td>29-07-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2423267 AI</td>
<td>24-03-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1469761 A</td>
<td>21-01-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 10047637 AI</td>
<td>25-04-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1324793 AI</td>
<td>09-07-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2234857 T3</td>
<td>01-07-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 154933 A</td>
<td>28-03-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2004508917 A</td>
<td>25-03-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MX PA03002632 A</td>
<td>10-09-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 1324793 E</td>
<td>29-04-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003187405 AI</td>
<td>02-10-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0226297 AI</td>
<td>04-04-2002</td>
</tr>
<tr>
<td>wo 2008015066 AI</td>
<td>07-02-2008</td>
<td>CN 101495566 A</td>
<td>29-07-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2049595 AI</td>
<td>22-04-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2009545347 A</td>
<td>24-12-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2009177150 AI</td>
<td>09-07-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2008015066 AI</td>
<td>07-02-2008</td>
</tr>
<tr>
<td>wo 2009030975 AI</td>
<td>12-03-2009</td>
<td>NONE</td>
<td></td>
</tr>
</tbody>
</table>